CCR2 and neoplasm: Given the synergistic benefits of PF-04136309, a small molecule CCR2 inhibitor, when administered together with chemotherapy in locally advanced pancreatic cancer patients [105], there is a good chance that nanoparticles directing chemokine receptor blocking agents to the bone marrow and the spleen might improve responses to cancer immunotherapy via blocking the recruitment of tumor infiltrating MDSC.